更新于：2024-12-09
Lactitol
拉克替醇
更新于：2024-12-09
概要
基本信息
结构
分子式C12H24O11 |
InChIKeyVQHSOMBJVWLPSR-JVCRWLNRSA-N |
CAS号585-86-4 |
关联
5
项与 拉克替醇 相关的临床试验A Randomized, Double-Blind, Active-Controlled, 4-week Parallel GroupStudy to Evaluate the Efficacy and Safety of Lactitol and Probiotic Bacillus Coagulans SC208 in patients with Chronic Idiopathic Constipation. - Lactiliq-TM Syrup
A Prospective, Randomised, Double-Blind, Placebo-Controlled, 4 week Parallel Group Study to Evaluate the Efficacy and Safety of Lactitol and Psyllium Alone and in Combination in Treatment of Constipation
Pilot Study of the Effectiveness of Probiotics and Lactitol for the Intestinal Decolonization of People Carriers of Klebsiella Pneumoniae Producers of Carbapenemase OXA-48-type: DesProbiOXA Study
100 项与 拉克替醇 相关的临床结果
登录后查看更多信息
100 项与 拉克替醇 相关的转化医学
登录后查看更多信息
100 项与 拉克替醇 相关的专利（医药）
登录后查看更多信息
268
项与 拉克替醇 相关的文献（医药）2024-08-30Journal of the science of food and agriculture
In vitro and in vivo digestibility of prebiotic galactooligosacharides synthesized by β‐galactosidase from Lactobacillus delbruecki subsp. bulgaricusCRL450
Article
作者: Hernández Hernández, Oswaldo ; Palacios, Jorge ; Zárate, Gabriela ; Fara, Agustina ; Montilla, Antonia
Abstract:
BACKGROUND:
The general assumption that prebiotics reach the colon without any alterations has been challenged. Some in vitro and in vivo studies have demonstrated that ‘non‐digestible’ oligosaccharides are digested to different degrees depending on their structural composition. In the present study, we compared different methods aiming to assess the digestibility of oligosaccharides synthesized by β‐galactosidase (β‐gal) of Lactobacillus delbruecki subsp. bulgaricus CRL450 (CRL450‐β‐gal) from lactose, lactulose and lactitol.
RESULTS:
In the simulated gastrointestinal fluid method, no changes were observed. However, the oligosaccharides synthesized by CRL450‐β‐gal were partially hydrolyzed in vitro, depending on their structure and composition, with rat small intestinal extract (RSIE) and small intestinal brush‐border membrane vesicles (BBMV) from pig. Digestion of some oligosaccharides increased when mixtures were fed to C57BL/6 mice used as in vivo model; however, lactulose‐oligosaccharides were the most resistant to the physiological conditions of mice. In general β (1→6) linked products showed higher resistance compared to β (1→3) oligosaccharides.
CONCLUSION:
In vitro digestion methods, without disaccharidases, may underestimate the importance of carbohydrates hydrolysis in the small intestine. Although BVMM and RSIE digestion assays are appropriate in vitro methods for these studies, in vivo studies remain the most reliable for understanding what actually happens in the digestion of oligosaccharides. © 2024 The Authors. Journal of The Science of Food and Agriculture published by John Wiley & Sons Ltd on behalf of Society of Chemical Industry.
2023-10-02Journal of environmental science and health. Part C, Toxicology and carcinogenesis
Determination of the genotoxic effects of sweeteners, mannitol and lactitol
Article
作者: Avuloglu-Yilmaz, Ece ; Eker-Kartal, Ebru
The changes in dietary habit around the world have led to an increased use of additives in the food. The safety of food additives has been a main focus of research for many years due to the ongoing debate on their potential effects on health. In this study, the in vitro genotoxic effects of mannitol and lactitol, polyols used as sweetener food additives, were evaluated using chromosomal aberrations (CAs) and micronucleus (MN) assays in human peripheral lymphocytes. Additionally, the effects of these sweeteners on the mitotic index (MI) and nuclear division index (NDI) were investigated. Concentrations of 500, 1000, 2000, 4000, and 8000 μg/mL for mannitol and 250, 500, 1000, 2000, and 4000 μg/mL for lactitol were used. The results indicated that both polyols did not affect CA and MN frequency, and did not cause a significant change in NDI at all treatment concentratoins. However, mannitol (except at concentrations of 500 and 1000 μg/mL) and lactitol (except at 250 μg/mL) significantly decreased the MI compared to the control at almost all concentrations and treatment times. In conclusion, it was observed that mannitol and lactitol did not have a significant genotoxic effect at the concentrations used in human lymphocytes in vitro.
2023-09-22Medicine
Primary prevention of hepatic encephalopathy post-TIPS: A systematic review and meta-analysis
Review
作者: Liang, Aileen ; Khan, Mohammad Qasim ; Brar, Sukhman ; Teriaky, Anouar ; Almaghrabi, Majed ; Qumosani, Karim
Background::
Transjugular intrahepatic portosystemic shunt (TIPS) can be an effective treatment for cirrhotic patients who develop variceal bleeding and ascites. However, TIPS placement is associated with an increased risk of developing hepatic encephalopathy (HE). Recently, there have been efforts to use the typical medical therapies prophylactically in patients undergoing TIPS placement to prevent post-TIPS HE.
Methods::
We conducted literature searches in MEDLINE, Embase, CINAHL, Scopus, and Cochrane to examine studies that use prophylactic medical therapy for preventing post-TIPS HE. A narrative synthesis and grading of recommendations assessment assessment were done for all studies. Meta-analysis was performed for eligible studies using the Mantel-Haenszel method random-effects model. Nine hundred twenty-one articles were screened and 5 studies were included in the study after 2 levels of screening. The medications studied were rifaximin, lactulose, lactitol, L-Ornithine-L-aspartate (LOLA), albumin, and combination therapies.
Results::
Narrative results showed that lactulose, lactitol, LOLA and albumin prophylaxis were not associated with reduction in HE occurrence or mortality. A combination of rifaximin and lactulose was found to be associated with lower occurrence of HE, and the results were not different when LOLA was added. Meta-analysis (n = 3) showed that rifaximin treatment was not associated with changes in HE occurrences.
Conclusion::
In conclusion, a vast majority of medications were not found to be effective post-TIPS HE prophylaxis when used alone. A rifaximin and lactulose combination therapy may be beneficial. Overall, there is significant limitation in the current data and more studies are needed to yield more robust meta-analysis results in the future.
4
项与 拉克替醇 相关的新闻（医药）2023-02-27
2023-02-12
2022-05-26
放射疗法抗体小分子药物抗体药物偶联物免疫疗法
100 项与 拉克替醇 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性特发性便秘 | 美国 | 2020-02-12 | |
| 便秘 | - | - | 1985-01-01 |
| 肝病 | - | - | 1985-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用